-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In November of this year, the total number of newly launched clinical trials led by corporate capital was 835, a decrease of 2.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
November, reporting the largest number of clinical trials company Novartis, to declare the number is 25; ranked in the following AstraZeneca and Takeda Pharmaceuticals, respectively 21 and 18
.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
From the new clinical trial in November indications point of view, respiratory disease is the most popular field of research and development, the number of new clinical trials carried out 114, and up by 8.
80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
From the perspective of drug types, statistics on the number of newly launched clinical trials found that the number of drug clinical trials in November showed an overall downward trend
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
Statistics on the origin of clinical trial applications found that the United States is the country with the most clinical trials; followed by China and Canada
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)
In November of this year, the total number of newly launched clinical trials led by corporate capital was 835, a decrease of 2.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
November, reporting the largest number of clinical trials company Novartis, to declare the number is 25; ranked in the following AstraZeneca and Takeda Pharmaceuticals, respectively 21 and 18
.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
From the new clinical trial in November indications point of view, respiratory disease is the most popular field of research and development, the number of new clinical trials carried out 114, and up by 8.
80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
From the perspective of drug types, statistics on the number of newly launched clinical trials found that the number of drug clinical trials in November showed an overall downward trend
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
Statistics on the origin of clinical trial applications found that the United States is the country with the most clinical trials; followed by China and Canada
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)
In November of this year, the total number of newly launched clinical trials led by corporate capital was 835, a decrease of 2.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
11% from October.
The number of newly launched clinical trials in a single month fell for the first time during the year; the number of new clinical trials that month accounted for 1-11 of this year 10.
07% of the total number of new additions in the month was higher than the average
.
November, reporting the largest number of clinical trials company Novartis, to declare the number is 25; ranked in the following AstraZeneca and Takeda Pharmaceuticals, respectively 21 and 18
.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
Enterprise business enterprise.
Companies with the largest increase in the number of new clinical trials were Takeda Pharmaceuticals and AbbVie, with monthly increases of 80% and 117%, respectively; companies with a significant decrease in the number of new clinical trials were AstraZeneca, Merck and Pfizer, among which Pfizer declined.
The largest, a drop of 31.
82%
.
Compared with 2020, the company with the biggest change in the number of newly launched clinical trials from January to November this year is GlaxoSmithKline, which has risen by 8 places
.
From the new clinical trial in November indications point of view, respiratory disease is the most popular field of research and development, the number of new clinical trials carried out 114, and up by 8.
80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
Disease disease disease tumor tumor tumor80%
.
New clinical trials for major hot indications in November (including respiratory diseases, tissue classification tumors , infectious diseases, immune system diseases, lung diseases, dermatological diseases, digestive system diseases, malignant epithelioma diseases, viral diseases, blood diseases) The number has generally declined compared with the previous month.
Among them, the largest decline was in viral diseases, with a drop of 32.
18%; the indications with a higher growth rate in the number of new clinical trials were malignant epithelioma diseases and hematological diseases
.
From the perspective of drug types, statistics on the number of newly launched clinical trials found that the number of drug clinical trials in November showed an overall downward trend
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
.
Among the Top10 popular drug types, hormones and hormone antagonists have the most significant decline
.
The number of newly launched clinical trials for both in a single month has decreased by more than 40% month-on-month .
Statistics on the origin of clinical trial applications found that the United States is the country with the most clinical trials; followed by China and Canada
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)
.
Compared with October, in the United States, China, Canada, the United Kingdom, Germany, Japan, Spain, Australia, South Korea, and Italy that have applied for more clinical trials, only Japan has increased in number, with 30 new projects, an increase of 15.
38 %; Australia and Spain dropped more, with a decrease of 46% and 40% respectively
.
(Data source: US Clinicaltrial Database)